Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis
Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effe...
Gespeichert in:
Veröffentlicht in: | Journal of cellular physiology 2018-07, Vol.233 (7), p.5458-5467 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 5467 |
---|---|
container_issue | 7 |
container_start_page | 5458 |
container_title | Journal of cellular physiology |
container_volume | 233 |
creator | Hsu, Hsi‐Hsien Chen, Ming‐Cheng Baskaran, Rathinasamy Lin, Yueh‐Min Day, Cecilia H. Lin, Yi‐Jiun Tu, Chuan‐Chou Vijaya Padma, Viswanadha Kuo, Wei‐Wen Huang, Chih‐Yang |
description | Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same.
Present study was designed to evaluate plausible role of ABCG2, multi drug resistance protein and associated pathway involved in OXA‐R LoVo cells. Our data show that oxaliplatin resistant LoVo colon cells are resistant to oxaliplatin, 5‐FU, and doxorubicin. Multi drug resistance acquired by overexpression of ABCG2 and p‐NF‐κB and downregulation of ER stress protein thereby preventing apoptosis. |
doi_str_mv | 10.1002/jcp.26406 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1977778963</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1977778963</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4196-16215a23495ec492872bacc721696025e80b46eabaa7cc0a08c5143818191a2c3</originalsourceid><addsrcrecordid>eNp1kcFPHCEUxomxqVvtwX_AkHiph1FgGGY46kZtGxMb057J27dswoYdRmC29dK_XaarHkzKhQC_7-O99xFyzNk5Z0xcrHE4F0oytUdmnOm2kqoR-2RW3nilG8kPyKeU1owxrev6IzkQWshWdt2M_L3_A94NHrLrabTJpQw9WlpOGHyIFjN4itNdpGi9T9QlurFLB9ku6dYBBcxuW_Shp2FFL6_mt4LmQMF7u50oev1AUy7eRdovRywyGMKQQ_nsiHxYgU_288t-SH7dXP-cf63u7m-_zS_vKpRcq4orwRsQtdSNRalF14oFILaCK62YaGzHFlJZWAC0iAxYhw2Xdcc7rjkIrA_Jl53vEMPjaFM2G5emdqC3YUyG67asTqu6oKfv0HUYY1-qM4LxaYC61YU621EYQ0rRrswQ3Qbik-HMTKGYEor5F0phT14cx0WZ3Bv5mkIBLnbAb-ft0_-dzPf5j53lM2GDlZQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2019933979</pqid></control><display><type>article</type><title>Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><creator>Hsu, Hsi‐Hsien ; Chen, Ming‐Cheng ; Baskaran, Rathinasamy ; Lin, Yueh‐Min ; Day, Cecilia H. ; Lin, Yi‐Jiun ; Tu, Chuan‐Chou ; Vijaya Padma, Viswanadha ; Kuo, Wei‐Wen ; Huang, Chih‐Yang</creator><creatorcontrib>Hsu, Hsi‐Hsien ; Chen, Ming‐Cheng ; Baskaran, Rathinasamy ; Lin, Yueh‐Min ; Day, Cecilia H. ; Lin, Yi‐Jiun ; Tu, Chuan‐Chou ; Vijaya Padma, Viswanadha ; Kuo, Wei‐Wen ; Huang, Chih‐Yang</creatorcontrib><description>Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same.
Present study was designed to evaluate plausible role of ABCG2, multi drug resistance protein and associated pathway involved in OXA‐R LoVo cells. Our data show that oxaliplatin resistant LoVo colon cells are resistant to oxaliplatin, 5‐FU, and doxorubicin. Multi drug resistance acquired by overexpression of ABCG2 and p‐NF‐κB and downregulation of ER stress protein thereby preventing apoptosis.</description><identifier>ISSN: 0021-9541</identifier><identifier>EISSN: 1097-4652</identifier><identifier>DOI: 10.1002/jcp.26406</identifier><identifier>PMID: 29247488</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>ABCG2 ; Animals ; Apoptosis ; Apoptosis - drug effects ; ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics ; Biomarkers, Tumor - genetics ; Cancer ; cancer stem cell ; Cell Proliferation - genetics ; Chemotherapy ; Colon ; Colon cancer ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Doxorubicin ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Drug resistance ; Drug Resistance, Neoplasm - genetics ; Endoplasmic Reticulum Stress - genetics ; Exposure ; G2 phase ; Gene expression ; Gene Expression Regulation, Neoplastic - drug effects ; Humans ; In vivo methods and tests ; Inhibitors ; Intracellular signalling ; Markers ; Metastases ; Mice ; mRNA ; multi drug resistance ; Multidrug resistance ; Neoplasm Proteins - genetics ; Oxaliplatin ; Oxaliplatin - administration & dosage ; Oxaliplatin - adverse effects ; Phosphorylation ; Platinum ; Proteins ; Stresses ; Verapamil ; Xenograft Model Antitumor Assays</subject><ispartof>Journal of cellular physiology, 2018-07, Vol.233 (7), p.5458-5467</ispartof><rights>2017 Wiley Periodicals, Inc.</rights><rights>2018 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4196-16215a23495ec492872bacc721696025e80b46eabaa7cc0a08c5143818191a2c3</citedby><cites>FETCH-LOGICAL-c4196-16215a23495ec492872bacc721696025e80b46eabaa7cc0a08c5143818191a2c3</cites><orcidid>0000-0003-2347-0411</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcp.26406$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcp.26406$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29247488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hsu, Hsi‐Hsien</creatorcontrib><creatorcontrib>Chen, Ming‐Cheng</creatorcontrib><creatorcontrib>Baskaran, Rathinasamy</creatorcontrib><creatorcontrib>Lin, Yueh‐Min</creatorcontrib><creatorcontrib>Day, Cecilia H.</creatorcontrib><creatorcontrib>Lin, Yi‐Jiun</creatorcontrib><creatorcontrib>Tu, Chuan‐Chou</creatorcontrib><creatorcontrib>Vijaya Padma, Viswanadha</creatorcontrib><creatorcontrib>Kuo, Wei‐Wen</creatorcontrib><creatorcontrib>Huang, Chih‐Yang</creatorcontrib><title>Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis</title><title>Journal of cellular physiology</title><addtitle>J Cell Physiol</addtitle><description>Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same.
Present study was designed to evaluate plausible role of ABCG2, multi drug resistance protein and associated pathway involved in OXA‐R LoVo cells. Our data show that oxaliplatin resistant LoVo colon cells are resistant to oxaliplatin, 5‐FU, and doxorubicin. Multi drug resistance acquired by overexpression of ABCG2 and p‐NF‐κB and downregulation of ER stress protein thereby preventing apoptosis.</description><subject>ABCG2</subject><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cancer</subject><subject>cancer stem cell</subject><subject>Cell Proliferation - genetics</subject><subject>Chemotherapy</subject><subject>Colon</subject><subject>Colon cancer</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Doxorubicin</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm - genetics</subject><subject>Endoplasmic Reticulum Stress - genetics</subject><subject>Exposure</subject><subject>G2 phase</subject><subject>Gene expression</subject><subject>Gene Expression Regulation, Neoplastic - drug effects</subject><subject>Humans</subject><subject>In vivo methods and tests</subject><subject>Inhibitors</subject><subject>Intracellular signalling</subject><subject>Markers</subject><subject>Metastases</subject><subject>Mice</subject><subject>mRNA</subject><subject>multi drug resistance</subject><subject>Multidrug resistance</subject><subject>Neoplasm Proteins - genetics</subject><subject>Oxaliplatin</subject><subject>Oxaliplatin - administration & dosage</subject><subject>Oxaliplatin - adverse effects</subject><subject>Phosphorylation</subject><subject>Platinum</subject><subject>Proteins</subject><subject>Stresses</subject><subject>Verapamil</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0021-9541</issn><issn>1097-4652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFPHCEUxomxqVvtwX_AkHiph1FgGGY46kZtGxMb057J27dswoYdRmC29dK_XaarHkzKhQC_7-O99xFyzNk5Z0xcrHE4F0oytUdmnOm2kqoR-2RW3nilG8kPyKeU1owxrev6IzkQWshWdt2M_L3_A94NHrLrabTJpQw9WlpOGHyIFjN4itNdpGi9T9QlurFLB9ku6dYBBcxuW_Shp2FFL6_mt4LmQMF7u50oev1AUy7eRdovRywyGMKQQ_nsiHxYgU_288t-SH7dXP-cf63u7m-_zS_vKpRcq4orwRsQtdSNRalF14oFILaCK62YaGzHFlJZWAC0iAxYhw2Xdcc7rjkIrA_Jl53vEMPjaFM2G5emdqC3YUyG67asTqu6oKfv0HUYY1-qM4LxaYC61YU621EYQ0rRrswQ3Qbik-HMTKGYEor5F0phT14cx0WZ3Bv5mkIBLnbAb-ft0_-dzPf5j53lM2GDlZQ</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Hsu, Hsi‐Hsien</creator><creator>Chen, Ming‐Cheng</creator><creator>Baskaran, Rathinasamy</creator><creator>Lin, Yueh‐Min</creator><creator>Day, Cecilia H.</creator><creator>Lin, Yi‐Jiun</creator><creator>Tu, Chuan‐Chou</creator><creator>Vijaya Padma, Viswanadha</creator><creator>Kuo, Wei‐Wen</creator><creator>Huang, Chih‐Yang</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2347-0411</orcidid></search><sort><creationdate>201807</creationdate><title>Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis</title><author>Hsu, Hsi‐Hsien ; Chen, Ming‐Cheng ; Baskaran, Rathinasamy ; Lin, Yueh‐Min ; Day, Cecilia H. ; Lin, Yi‐Jiun ; Tu, Chuan‐Chou ; Vijaya Padma, Viswanadha ; Kuo, Wei‐Wen ; Huang, Chih‐Yang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4196-16215a23495ec492872bacc721696025e80b46eabaa7cc0a08c5143818191a2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>ABCG2</topic><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cancer</topic><topic>cancer stem cell</topic><topic>Cell Proliferation - genetics</topic><topic>Chemotherapy</topic><topic>Colon</topic><topic>Colon cancer</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Doxorubicin</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm - genetics</topic><topic>Endoplasmic Reticulum Stress - genetics</topic><topic>Exposure</topic><topic>G2 phase</topic><topic>Gene expression</topic><topic>Gene Expression Regulation, Neoplastic - drug effects</topic><topic>Humans</topic><topic>In vivo methods and tests</topic><topic>Inhibitors</topic><topic>Intracellular signalling</topic><topic>Markers</topic><topic>Metastases</topic><topic>Mice</topic><topic>mRNA</topic><topic>multi drug resistance</topic><topic>Multidrug resistance</topic><topic>Neoplasm Proteins - genetics</topic><topic>Oxaliplatin</topic><topic>Oxaliplatin - administration & dosage</topic><topic>Oxaliplatin - adverse effects</topic><topic>Phosphorylation</topic><topic>Platinum</topic><topic>Proteins</topic><topic>Stresses</topic><topic>Verapamil</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hsu, Hsi‐Hsien</creatorcontrib><creatorcontrib>Chen, Ming‐Cheng</creatorcontrib><creatorcontrib>Baskaran, Rathinasamy</creatorcontrib><creatorcontrib>Lin, Yueh‐Min</creatorcontrib><creatorcontrib>Day, Cecilia H.</creatorcontrib><creatorcontrib>Lin, Yi‐Jiun</creatorcontrib><creatorcontrib>Tu, Chuan‐Chou</creatorcontrib><creatorcontrib>Vijaya Padma, Viswanadha</creatorcontrib><creatorcontrib>Kuo, Wei‐Wen</creatorcontrib><creatorcontrib>Huang, Chih‐Yang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cellular physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hsu, Hsi‐Hsien</au><au>Chen, Ming‐Cheng</au><au>Baskaran, Rathinasamy</au><au>Lin, Yueh‐Min</au><au>Day, Cecilia H.</au><au>Lin, Yi‐Jiun</au><au>Tu, Chuan‐Chou</au><au>Vijaya Padma, Viswanadha</au><au>Kuo, Wei‐Wen</au><au>Huang, Chih‐Yang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis</atitle><jtitle>Journal of cellular physiology</jtitle><addtitle>J Cell Physiol</addtitle><date>2018-07</date><risdate>2018</risdate><volume>233</volume><issue>7</issue><spage>5458</spage><epage>5467</epage><pages>5458-5467</pages><issn>0021-9541</issn><eissn>1097-4652</eissn><abstract>Oxaliplatin (OXA), is a third generation platinum drug used as first‐line chemotherapy in colorectal cancer (CRC). Cancer cells acquires resistance to anti‐cancer drug and develops resistance. ATP‐binding cassette (ABC) drug transporter ABCG2, one of multidrug resistance (MDR) protein which can effectively discharge a wide spectrum of chemotherapeutic agents out of cancer cells and subsequently reduce the intracellular concentration of these drugs. Role of ABCG2 and plausible molecular signaling pathways involved in Oxaliplatin‐Resistant (OXA‐R) colon cancer cells was evaluated in the present study. OXA resistant LoVo cells was developed by exposing the colon cells to OXA in a dose‐dependent manner. Development of multi drug resistance in OXA‐R cells was confirmed by exposing the resistance cells to oxaliplatin, 5‐FU, and doxorubicin. OXA treatment resulted in G2 phase arrest in parental LoVo cells, which was overcome by OXA‐R LoVo cells. mRNA and protein expression of ABCG2 and phosphorylation of NF‐κB was significantly higher in OXA‐R than parental cells. Levels of ER stress markers were downregulated in OXA‐R than parental cells. OXA‐R LoVo cells exposed to NF‐κB inhibitor QNZ effectively reduced the ABCG2 and p‐NF‐κB expression and increased ER stress marker expression. On other hand, invasion and migratory effect of OXA‐R cells were found to be decreased, when compared to parental cells. Metastasis marker proteins also downregulated in OXA‐R cells. ABCG2 inhibitor verapamil, downregulate ABCG2, induce ER stress markers and induces apoptosis. In vivo studies in nude mice also confirms the same.
Present study was designed to evaluate plausible role of ABCG2, multi drug resistance protein and associated pathway involved in OXA‐R LoVo cells. Our data show that oxaliplatin resistant LoVo colon cells are resistant to oxaliplatin, 5‐FU, and doxorubicin. Multi drug resistance acquired by overexpression of ABCG2 and p‐NF‐κB and downregulation of ER stress protein thereby preventing apoptosis.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29247488</pmid><doi>10.1002/jcp.26406</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-2347-0411</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9541 |
ispartof | Journal of cellular physiology, 2018-07, Vol.233 (7), p.5458-5467 |
issn | 0021-9541 1097-4652 |
language | eng |
recordid | cdi_proquest_miscellaneous_1977778963 |
source | Wiley Online Library - AutoHoldings Journals; MEDLINE |
subjects | ABCG2 Animals Apoptosis Apoptosis - drug effects ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics Biomarkers, Tumor - genetics Cancer cancer stem cell Cell Proliferation - genetics Chemotherapy Colon Colon cancer Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Doxorubicin Doxorubicin - administration & dosage Doxorubicin - adverse effects Drug resistance Drug Resistance, Neoplasm - genetics Endoplasmic Reticulum Stress - genetics Exposure G2 phase Gene expression Gene Expression Regulation, Neoplastic - drug effects Humans In vivo methods and tests Inhibitors Intracellular signalling Markers Metastases Mice mRNA multi drug resistance Multidrug resistance Neoplasm Proteins - genetics Oxaliplatin Oxaliplatin - administration & dosage Oxaliplatin - adverse effects Phosphorylation Platinum Proteins Stresses Verapamil Xenograft Model Antitumor Assays |
title | Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T19%3A06%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxaliplatin%20resistance%20in%20colorectal%20cancer%20cells%20is%20mediated%20via%20activation%20of%20ABCG2%20to%20alleviate%20ER%20stress%20induced%20apoptosis&rft.jtitle=Journal%20of%20cellular%20physiology&rft.au=Hsu,%20Hsi%E2%80%90Hsien&rft.date=2018-07&rft.volume=233&rft.issue=7&rft.spage=5458&rft.epage=5467&rft.pages=5458-5467&rft.issn=0021-9541&rft.eissn=1097-4652&rft_id=info:doi/10.1002/jcp.26406&rft_dat=%3Cproquest_cross%3E1977778963%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2019933979&rft_id=info:pmid/29247488&rfr_iscdi=true |